title: Efficacy of sarolaner in the prevention of Borrelia burgdorferi and Anaplasma phagocytophilum transmission from infected Ixodes scapularis to dogs.
abstract: The efficacy of sarolaner (Simparica™, Zoetis) to prevent transmission primarily of Borrelia burgdorferi and secondarily of Anaplasma phagocytophilum from infected wild-caught Ixodes scapularis to dogs was evaluated in a placebo-controlled laboratory study. Twenty-four purpose-bred laboratory Beagles seronegative for B. burgdorferi and A. phagocytophilum antibodies were allocated randomly to one of three treatment groups: placebo administered orally on Days 0 and 7, or sarolaner at 2mg/kg administered orally on Day 0 (28 days prior to tick infestation) or on Day 7 (21 days prior to tick infestation). On Day 28, each dog was infested with approximately 25 female and 25 male wild caught adult I. scapularis that were determined to have prevalence of 57% for B. burgdorferi and 6.7% for A. phagocytophilum by PCR. In situ tick counts were conducted on Days 29 and 30. On Day 33, all ticks were counted and removed. Acaricidal efficacy was calculated based on the reduction of geometric mean live tick counts in the sarolaner-treated groups compared to the placebo-treated group for each tick count. Blood samples collected from each dog on Days 27, 49, 63, 77, 91 and 104 were tested for the presence of B. burgdorferi and A. phagocytophilum antibodies using the SNAP(®) 4Dx(®) Plus Test, and quantitatively assayed for B. burgdorferi antibodies using an ELISA test. Skin biopsies collected on Day 104 were tested for the presence of B. burgdorferi by bacterial culture and PCR. Geometric mean live tick counts for placebo-treated dogs were 14.8, 12.8, and 19.1 on Days 29, 30, and 33, respectively. The percent reductions in mean live tick counts at 1, 2, and 5 days after infestation were 86.3%, 100%, and 100% for the group treated with sarolaner 21 days prior to infestation, and 90.9%, 97.1%, and 100% for the group treated with sarolaner 28 days prior to infestation. Geometric mean live tick counts for both sarolaner-treated groups were significantly lower than those for the placebo group on all count days (P<0.0001). There were no adverse reactions to treatment with sarolaner. Transmission of B. burgdorferi to all eight placebo-treated dogs was confirmed by positive antibody (6 of 8 dogs), PCR (7 of 8 dogs), and/or culture (7 of 8 dogs). Similarly, transmission of A. phagocytophilum was confirmed by the presence of antibodies in four placebo-treated dogs. In contrast, treatment with a single dose of sarolaner prevented transmission of B. burgdorferi from infected ticks to dogs infested 21 or 28 days after treatment as demonstrated by negative antibody, PCR, and culture results. Prevention of transmission of A. phagocytophilum was demonstrated by negative antibody results in all sarolaner-treated dogs.
authors.affiliation: Zoetis, Veterinary Medicine Research and Development, 333 Portage St. Kalamazoo, MI 49007, USA.
authors.forename: Nicole A
authors.initials: NA
authors.lastname: Honsberger
authors.affiliation: Zoetis, Veterinary Medicine Research and Development, 333 Portage St. Kalamazoo, MI 49007, USA. Electronic address: robert.six@Zoetis.com.
authors.forename: Robert H
authors.initials: RH
authors.lastname: Six
authors.affiliation: Zoetis, Veterinary Medicine Research and Development, 333 Portage St. Kalamazoo, MI 49007, USA.
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Heinz
authors.affiliation: Zoetis, Veterinary Medicine Research and Development, 333 Portage St. Kalamazoo, MI 49007, USA.
authors.forename: Angela
authors.initials: A
authors.lastname: Weber
authors.affiliation: Zoetis, Veterinary Medicine Research and Development, 333 Portage St. Kalamazoo, MI 49007, USA.
authors.forename: Sean P
authors.initials: SP
authors.lastname: Mahabir
authors.affiliation: Zoetis, Veterinary Medicine Research and Development, 333 Portage St. Kalamazoo, MI 49007, USA.
authors.forename: Thomas C
authors.initials: TC
authors.lastname: Berg
mesh_terms: D056810:Acaricides / Q000627:therapeutic use; D041081:Anaplasma phagocytophilum / Q000502:physiology; D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood; D001096:Arachnid Vectors / Q000382:microbiology; D025065:Borrelia burgdorferi / Q000502:physiology; D018562:Disease Transmission, Infectious / Q000517:prevention & control / Q000662:veterinary*; D004283:Dog Diseases / Q000188:drug therapy* / Q000517:prevention & control* / Q000635:transmission; D004285:Dogs; D016873:Ehrlichiosis / Q000517:prevention & control / Q000635:transmission / Q000662:veterinary*; D005260:Female; D007555:Isoxazoles / Q000627:therapeutic use*; D018884:Ixodes / Q000382:microbiology; D008193:Lyme Disease / Q000517:prevention & control / Q000635:transmission / Q000662:veterinary*; D008297:Male; D013984:Tick Infestations / Q000188:drug therapy / Q000662:veterinary*; D016896:Treatment Outcome
chemical_list: D056810:Acaricides; D000907:Antibodies, Bacterial; D007555:Isoxazoles
keywords: Anaplasma phagocytophilum; Borrelia burgdorferi; Dog; Isoxazoline; Ixodes scapularis; Lyme; Sarolaner; Simparica™; Tick borne disease; Ticks; Vector borne disease